Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.

Cancer medicine - 1 Jun 2023

Kim Ji-Yeon, Jung Jaeyun, Kim Kyoung-Mee, Lee Jeeyun, Im Young-Hyuck

Abstract excerpt

BACKGROUND: TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53's DNA binding domain. The aim of this study was to explain the reason why R175H worse the response to immunotherapy by analyzing tumor immune microenvironment through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Programmed Cell Death 1 Receptor

Share to Repressor Proteins

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 37081749
DOI: 10.1002/cam4.5953
PMCID: PMC10278489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.PMID 37081749Read ↗

TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer PatientsSemantic proximity Read ↗

TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 DatabaseSemantic proximity Read ↗

Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.Semantic proximity Read ↗

Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?Semantic proximity Read ↗

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.Semantic proximity Read ↗

TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma.Semantic proximity Read ↗

TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selectionSemantic proximity Read ↗

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.Semantic proximity Read ↗

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.Semantic proximity Read ↗

TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapySemantic proximity Read ↗

Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.Semantic proximity Read ↗

mTORC1 Suppression by Trp53 Mutation Drives Resistance to Immune Checkpoint BlockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.